Mutations in the presenilin-1 (PS-1) gene on chromosome 14 account for the majority of earlyonset familial Alzheimer's disease (FAD) cases. To date, more than 90 mutations have been identified and, while most of these mutations are completely penetrant, the Glu318Gly mutation has been suggested to be partially penetrant. These findings indicate that it may play a similar role to apolipoprotein E (APOE)-⑀4 by acting as a genetic risk factor for AD. In the current study, a total of 682 subjects were tested to assess the frequency of the Glu318Gly mutation in AD in the Australian population. The Glu318Gly mutation was identified in six sporadic late-onset AD patients, four FAD patients (unrelated) and in nine control subjects. The frequency of this mutation was highest in the familial AD group (8.7%) and lowest in control subjects (2.2%). When the mutation frequencies were compared, we found a statistically significant difference between the latter two groups (Fisher's exact test, P Ͻ 0.05). The genotype frequency of the Glu318Gly mutation in all AD cases and controls in the Australian population was 2.8%. This frequency is comparable to that observed for the Dutch population (3.2%), but not for the Finnish population (6.8% and 6.0%) or the Spanish population (5.3%). These findings show that the frequency of the Glu318Gly mutation is increased in FAD patients, suggesting a potential role as a genetic risk factor contributing to the pathogenesis of familial AD.
Introduction
Most cases of early-onset Alzheimer's disease (EOAD) are associated with mutations in the presenilin-1 gene (PS-1) 1 on chromosome 14 and are inherited in an autosomal dominant fashion. The PS-1 gene consists of 10 coding (exons [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] and three non-coding exons (exons 1A, 1B and 2) which specify a 467-amino acid protein predicted to contain 6-9 1-4 transmembrane domains and to include a large hydrophilic loop region (amino acids 267-403). To date, more than 90 different mutations, 1,5-11 mainly missense mutations, in the PS-1 gene have been identified in more than 90 families of various ethnic origins. 12 These mutations are highly penetrant, resulting in an early age of onset. Patients carrying the same PS-1 mutation usually display very similar ages of onset. 13 One exception, however, is the Glu318Gly mutation, caused by an A to G transition at codon 318 in exon 9 of PS-1, which exhibits a variable age of onset for AD ranging from 35-64 years. 7 The pathogenicity of this mutation has been questioned since it has been found in a number of non-demented control individuals in addition to having been found in early-and late-onset AD patients without a known family history, [14] [15] [16] and in familial AD patients. 9, 17, 18 This finding has led researchers to suggest that the Glu318Gly mutation is either a rare polymorphism, 12, 19, 20 a neutral mutation, 21 or a mutation with incomplete penetrance 21 leading to the disease only in a subset of cases. In the current study, we determined the frequency of the Glu318Gly mutation in 682 Caucasians with either familial AD, early-or late-onset sporadic AD, or age-matched controls from the Australian population, in an attempt to clarify the role of this mutation in Alzheimer's disease.
Methods

Participants
With approval from our institute's ethics committee, the frequency of the Glu318Gly mutation was determined in 682 individuals, which included 43 sporadic EOAD patients (42% female, mean age 62 years, range 42-71), 191 sporadic late-onset AD (LOAD) patients (61% female, mean age 80 years, range 64-95) and 46 familial AD patients (unrelated; 46% female, mean age 65 years, range 38-93). The 402 healthy controls (50% female, mean age 75 years, range 50-92) were Australian volunteers with no apparent cognitive deficits, who were spouses of AD afflicted individuals or were recruited from the same communities as the AD patients. Individuals were ambulatory, community dwelling, and recruited from memory evaluation units in Perth (436 individuals) and Sydney (246 individuals). No selection criteria other than voluntary participation were imposed. At recruitment, relevant individual details including age, race and family history were noted and patient consent was given for genetic testing to be undertaken. Of all the individuals used in this study, approximately 97% were Caucasian (Northern European descent). At both locations, diagnosis of dementia was made by experienced clinicians using DSM-IV criteria. 22 Cognition was quantified using the Cambridge Mental Disorders of the Elderly Examination (CAMDEX). 23 The designation of probable Alzheimer's disease was determined following the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) criteria. 24 Of the 43 sporadic EOAD patients, none had any mutation within the known AD genes (APP, PS-1 and PS-2) and no family history of EOAD was present. Of the 46 familial AD patients (unrelated; mean age of onset, 58 ± 10 years), four had a mutation other than the Glu318Gly in the PS-1 gene. Of the sporadic EOAD and familial AD Glu318Gly positive individuals, none were positive for other PS-1 mutations. No mutations were found either within exons 16 and 17 of the APP gene, nor were the most common PS-2 mutations (N1411 and M238V) detected in any of the patients. The disease was considered familial if at least one additional first degree relative suffered from dementia.
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Genetic screenings DNA for Glu318Gly screening was extracted from white blood cells using a standard protocol. 25 In order to identify the Glu318Gly mutation, PCR was performed as described, 20 using the forward 'mismatched' primer, 5Ј-ATCCAAAAATTCCAAGTATAATCCAG-3Ј and the reverse primer 5Ј-CTGGGCATTATCAT-AGTTCTCAAG-3Ј to generate a BstN1 site, followed by enzyme digestion (BstN1; New England Biolabs, MA, USA). APOE genotyping was performed as described before. 26 For the majority of subjects, the APOE genotype was known from previous studies. 27, 28 Statistical analyses The data were analysed using the statistical package 'SPSSv7.0' for Windows. Categorical variables were investigated using the Pearson method for the analysis of contingency tables ( 2 ). In cases where the smallest number in any one cell of a 2 × 2 table was less than 10, we used the Fisher's exact test for comparisons. Relative risks (odds ratios) were estimated from 2 × 2 tables. Ninety-five percent confidence intervals were estimated for the odd ratios (CI).
Results
We previously identified the Glu318Gly mutation by direct sequence analysis of PCR products amplified from a genomic DNA template of an individual with familial AD. 9 In the current study, a total of 682 Caucasian subjects were tested to assess the frequency of this mutation and to evaluate its contribution to AD in the Australian population. As shown in Table 1 , the Glu318Gly mutation was detected in six sporadic LOAD patients, in four familial AD patients (unrelated) and in nine control subjects. Of the 43 sporadic EOAD patients screened, none were found to have this mutation. The frequency of this mutation was highest in the familial AD group (8.7%), compared with 3.1% in the sporadic LOAD group and was lowest in control subjects (2.2%). When the mutation frequencies were compared by either the Pearson 2 method or Fisher's exact test, we found no significant difference between the sporadic LOAD group and control subjects (Fisher's exact test, P = 0.578). However, our results showed a significant difference (Fisher's exact test, P Ͻ 0.05) when we compared the familial AD group with agematched control subjects.
As reported by several groups including our own, 27 a significantly increased incidence of the APOE-⑀4 allele was observed from the data in the current study in all sporadic AD (n = 234) patients when compared to age-matched controls (n = 402; Pearson 2 = 45.412; P Ͻ 0.0001). The increased risk associated with at least one ⑀4 allele was greater than 3-fold (OR = 3.15; 95% CI = 2.24-4.42), while the presence of two ⑀4 alleles increased the risk of developing AD more than 8-fold (OR = 8.07; 95% CI = 2.87-22.74) when compared to non-⑀4 individuals. The APOE-⑀4 genotypic distribution within the control group (n = 402) was close to that expected under Hardy-Weinberg equilibrium ( test, P Ͼ 0.5). The genotypic frequencies of the Perth (n = 201, 2 test, P Ͼ 0.5) and Sydney (n = 201, 2 test, P Ͼ 0.8) control sample did not differ from that expected.
Of the 90 or more mutations identified so far in the PS-1 gene, no relationship between the inheritance of the APOE-⑀4 allele and age of AD onset has been shown. In order to test for an interaction between the Glu318Gly mutation and the APOE-⑀4 allele, we stratified the total sample by the absence or presence of one or two copies of the ⑀4 allele (Table 1 ). In both the absence (Fisher's exact test; P = 0.437) or the presence of at least one copy of the ⑀4 allele (Fisher's exact test; P = 1.000), there was no association between APOE genotype and the Glu318Gly mutation comparing sporadic LOAD patients with controls. Again, no significant difference was detected comparing familial AD patients with controls either in the absence (Fisher's exact test, P = 0.107) or presence (Fisher's exact test, P = 0.217) of at least one copy of the ⑀4 allele. Of the APOE-⑀4 homozygotes screened, only one sporadic LOAD patient carrying the Glu318Gly mutation was identified and none in the other groups.
In this study, we detected the Glu318Gly mutation in four familial AD patients from four unrelated families who had onset of disease at the ages of late 50s, 60, 64 and 69 years. Details of each proband's pedigree are shown in Table 2 . As with previous reports 14, [15] [16] [17] [18] for other ethnic groups, cosegregation of this mutation with AD could not be properly tested due to the lack of sufficient family members for analysis. In each of the families in this study, with the exception of the PERTH-7 family, the proband was the only affected member available for analysis. In the PERTH-7 family, an affected brother of the proband also had the mutation ( Table 2 ). The age of onset of the affected brother was 82 years compared to 60 years for the proband. This variable age of AD onset within this family with the Glu318Gly mutation suggests that the clinical effect/penetrance of this mutation per se is likely to be modifiable by other genetic or non-genetic events.
For each family, a number of unaffected relatives were available for analysis, with the exception of the PERTH-5 family where no unaffected member was available for screening. As can be seen in Table 2 , one of three unaffected relatives (two siblings and one first degree relative) screened from the PERTH-6 family has the Glu318Gly mutation. The unaffected Glu318Gly positive individual was studied at 35 years of age, as compared to the mean age of AD onset for this family of 64 ± 8 years, range 55-80 years. Thus, this 35-yearold individual may be considered as 'at risk'. This is also the case with the PERTH-8 family, where two siblings of the proband were available for analysis. Both siblings, aged 40 and 47 years were positive for the Glu318Gly mutation, but the mean age of AD onset for the family is 71 ± 2 years, range 69-73 years. Thus, both individuals are still 'at risk' of developing AD. For the PERTH-7 case, four unaffected relatives (a brother, sister and two siblings) were screened. Only the unaffected brother was positive for the Glu318Gly mutation and his age at the time of study was 81 years. Comparison of his age to the mean age of AD onset for the family (68 ± 11 years, range 59-83 years) does exclude him as an escapee.
Discussion
To assess the frequency of the Glu318Gly mutation and to evaluate its contribution to AD in the Australian population we screened sporadic early-(EOAD) and late-onset AD (LOAD) cases, familial AD cases and control subjects. None of the 43 sporadic EOAD patients screened were found to have this mutation. We found the frequency of the Glu318Gly mutation was highest in the familial AD group (8.7%), compared with 3.1% in the sporadic LOAD group and was lowest in control subjects (2.2%). When the mutation frequencies were compared by the Pearson 2 method, we found no significant difference between the sporadic LOAD group and control subjects (P = 0.513). This result for the Australian population is consistent with those of recent reports for other populations; eg, Mattila et al 12 found no significant difference in the frequency of the Glu318Gly mutation between familial AD patients and control subjects. However, our results showed a significant difference (P Ͻ 0.05) when we compared the familial AD group with age-matched control subjects. 16 who showed this variant to be significantly increased in both familial and sporadic AD cases. It is interesting to note that Mattila et al 12 and Helisalmi et al 16 report conflicting results for this variant in AD cases in the same Finnish population. Clarification of the role of this mutation as a possible risk factor for AD in the Finnish population must await further investigation of a much larger population. Upon comparing the frequency of the Glu318Gly mutation in control subjects across the various ethnic populations, we found the Australian population to have the lowest frequency (2.2%; nine carriers/402 individuals). The frequency in the control Dutch population is 4.1% (nine carriers/219 individuals), 20, 21 in the Finnish population, 6.8% (four carriers/59 individuals) 12 and 4.0% (10 carriers/270 individuals), 16 and in the Spanish population, 4.5% (four carriers/89 individuals). 19 The fact that the frequency of this mutation in controls is twice as high in these other populations, may be a contributing factor for the lack of association between the Glu318Gly mutation and AD in these populations. Therefore, analogous to the major genetic risk factor apolipoprotein E (APOE)-⑀4 allele, the association between the Glu318Gly mutation and familial AD may vary among different ethnic groups.
This is consistent with Helisalmi et al
In all AD cases as well as controls, we found the Glu318Gly mutation with a genotype frequency of 2.8% (19 carriers/682 individuals) in the Australian population. Comparing this frequency for the Glu318Gly mutation with those of other populations, we found the Australian population to have the lowest frequency. The genotype frequency of the Glu318Gly mutation in the Dutch population is 3.2% (22 carriers/676 individuals), 20, 21 in the Finish population, 6.8% (eight carriers/120 individuals), 12 and 6.0% (21 carriers/350 individuals), 16 and in the Spanish population, 5.3% (14 carriers/263 individuals). 19 Recently, PS-1 Glu318Gly has been reported to be a risk factor for AD. 9, [14] [15] [16] [17] [18] However, a number of groups
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have reported this variant as either a rare polymorphism, 12, 19, 20 a neutral mutation, 21 or a mutation with incomplete penetrance 21 leading to AD only in some cases, possibly in combination with other genetic and environmental factors. A number of recent findings have led some researchers to suggest a lack of pathogenicity of the Glu318Gly mutation in AD. 12, [19] [20] [21] Cruts and Van Broeckhoven, 7 noted that the Glu318 residue is located in the middle part of the hydrophilic loop VI, a region of the PS-1 protein that is weakly conserved in human PS-2, or in the presenilin-homologues Drosophila PS-1 and Caenorhabditis elegans SEL-12. Location of the Glu318Gly mutation in this site would be compatible with either the absence of pathogenic effects (polymorphism) or weak pathogenic effects (reduced penetrance). 12 The pathogenicity of the Glu318Gly mutation has been questioned because to date, it has not been possible to show co-segregation of this mutation with AD due to the lack of sufficient family members in all reported cases. For example, the Glu318Gly mutation was first reported in a German early-onset AD patient with an age of onset of approximately 47 years and without a known family history. 14 This same mutation was then detected in two AD patients belonging to a Swedish early-onset family 17 with onset ages of 60 and 68 years, and later in a Dutch familial AD patient with an age of onset of 57 years. 18 Three more patients with this mutation, from three different families, have been reported: one with an age of onset of 55 years but without a known family history, 15 a second with a similar age of onset, 15 and the third with an age of onset in the late 50s. 9 The latter two patients had a family history of AD.
Another confounding factor has been the variable age of AD onset associated with this mutation, ranging from 35-64 years. 7 The major argument in support of the Glu318Gly mutation being non-pathogenic stems from the observation that numerous non-demented control individuals with this mutation have been identified among various ethnic populations, which have similar frequencies to their corresponding AD populations. However, we have shown that the Glu318Gly frequency is increased in the AD group in the Australian population indicating that at least in this population this mutation may play a role in the pathogenesis of AD. Further genetic studies on other populations need to be undertaken to identify those populations that may be vulnerable to this mutation.
Functional studies have further questioned the pathogenicity of the Glu318Gly mutation. Dermaut et al 20, 21 found no difference in the level of A␤42 in conditioned media of HEK-293 cells stably transfected with the Glu318Gly mutation compared to stably transfected cells with wild-type PS-1. Unfortunately, the primary data were not displayed in the publication by Dermaut et al, 20, 21 and there was no indication whether the level of A␤42 had been compared with A␤42 levels from HEK-293 cells stably transfected with other known PS-1 pathogenic mutations. Furthermore, transfected cell lines may not be the best method for assessing whether A␤42 levels are increased in response to the Glu318Gly mutation, as it has been shown that other PS-1 mutations which are associated with varying degrees of clinical severity as determined by their ages of onset, do not exhibit corresponding differences in A␤42 production in transfected cell lines. 29, 30 Further studies with skin fibroblasts from individuals with the Glu318Gly mutation need to be undertaken to determine whether this mutation results in increased A␤42 levels as has been shown for other PS-1 mutations.
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Conclusion
The PS-1 mutation, Glu318Gly, is found in a high frequency in familial AD individuals in the Australian population. We found the frequency of this mutation in the familial AD group to be significantly increased as compared to control subjects. No interaction with the ⑀4 allele of APOE was observed. However, we propose that the Glu318Gly mutation may be conceptualised as playing a role in AD analogous to that played by APOE-⑀4: ie, by acting as a genetic risk factor for FAD. This report also reviews evidence that the association between the Glu318Gly mutation and FAD varies among different ethnic groups.
